Adam J. Gadzinski, MD, MS, on Up-and-Coming Research for Urologic Oncology

Video

The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.

In an interview with CancerNetwork®,Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, discussed encouraging research in the field of urologic oncology.

Transcription:

From a new treatment standpoint, some of [the most interesting] areas in prostate, kidney, and bladder cancer [are] the continued immunotherapy developments. Another one that’s very relevant to our world today is continued disparities research. [With] disparities, everyone always initially tends to think of gender and racial disparities; I think inherent into that [are] also very significant socioeconomic and also geographic disparities.

I think there’s going to be new ways of providing urologic care and telemedicine will be one tool for that. I do not think that…telemedicine will fix all disparity access issues for urologic care. I think that that is an over promise for this technology. But I think it can help and it can be used as a tool [for] the person who lives 500 miles away from a referral center [who has] a unique cancer that probably should…at least have treatment guided by that referral center. [This technology] makes it just a lot easier for them to get the input because they don’t have to drive 500 miles or fly that far. They can just have a telemedicine visit from their couch and say, ‘Okay, my local provider can do this, this is great. Thank you so much for your guidance and input,’ and [get] on with their day.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content